Notice of Investor Presentation

RNS Number : 1008K

Diaceutics PLC

31 August 2021

 

31 August 2021 

Diaceutics PLC

("Diaceutics" or the "Group" or the "Company")

Investor Presentation

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, today announces that Peter Keeling, CEO, and Philip White, CFO, will provide a live presentation relating to the Company's Interim results for the six months ending 30 June 2021 via the Investor Meet Company platform on 15 September 2021 at 3:30pm.

The presentation is open to all existing and potential shareholders and registration can be completed via the following link:

https://www.investormeetcompany.com/diaceutics-plc/register-investor

Questions should be submitted by 9am on 14 September 2021 through the Investor Meet Company dashboard or at any time during the live presentation.

Investors who already follow Diaceutics on the Investor Meet Company platform will automatically be invited.

Enquiries:

Diaceutics PLC
Philip White, Chief Financial Officer	Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker )	Tel: [phone]
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR	Tel: [phone]
Caroline Forde	[e-mail]
Robyn Fisher
Kieran Breheny Matthew Young

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

 

END

 

 

DOCXBLFXFVLBBBL